These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 2661369)

  • 21. Pharmacological implications from the adhesion-induced signaling profiles in cultured human retinal pigment epithelial cells.
    Wu WC; Chang YC; Wu KY; Chen SY; Hsieh MC; Wu MH; Wu HJ; Wu WS; Kao YH
    Kaohsiung J Med Sci; 2014 Jan; 30(1):1-11. PubMed ID: 24388052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Mononuclear phagocytes and their growth factors: pacemakers of proliferative vitreoretinopathy?].
    Weller M; Heimann K; Wiedemann P
    Klin Monbl Augenheilkd; 1990 Mar; 196(3):121-7. PubMed ID: 2188039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathological vitreous causes cell line-derived (but not donor-derived) retinal pigment epithelial cells to display proliferative vitreoretinopathy-like features in culture.
    Sharma M; Tiwari A; Sharma S; Bansal R; Gupta V; Gupta A; Luthra-Guptasarma M
    Clin Exp Ophthalmol; 2014 Nov; 42(8):745-60. PubMed ID: 24612444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A randomized, prospective study of the treatment of proliferative vitreoretinopathy with daunomycin].
    Wiedemann P; Lemmen KD; Wiedemann R; Moter H; Heimann K
    Fortschr Ophthalmol; 1988; 85(5):503-4. PubMed ID: 3066728
    [No Abstract]   [Full Text] [Related]  

  • 25. Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy.
    Berger AS; Cheng CK; Pearson PA; Ashton P; Crooks PA; Cynkowski T; Cynkowska G; Jaffe GJ
    Invest Ophthalmol Vis Sci; 1996 Oct; 37(11):2318-25. PubMed ID: 8843916
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood-ocular barrier breakdown.
    Sakamoto T; Miyazaki M; Hisatomi T; Nakamura T; Ueno A; Itaya K; Ishibashi T
    Graefes Arch Clin Exp Ophthalmol; 2002 Jun; 240(6):423-9. PubMed ID: 12107507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravitreal drug therapy.
    Peyman GA; Schulman JA
    Jpn J Ophthalmol; 1989; 33(4):392-404. PubMed ID: 2696799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effects of intravitreal steroid injection on rabbit eye].
    Shimada H; Matsui M
    Nippon Ganka Gakkai Zasshi; 1989 Apr; 93(4):501-10. PubMed ID: 2801353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Experimental Modeling of Proliferative Vitreoretinopathy. An Experimental Morphological Study.
    Khoroshilova-Maslova IP; Leparskaya NL; Nabieva MM; Andreeva LD
    Bull Exp Biol Med; 2015 May; 159(1):100-2. PubMed ID: 26033599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Proliferative vitreoretinopathy. On the significance of protein transfer through the blood-retina barrier].
    Grisanti S; Wiedemann P; Heimann K
    Ophthalmologe; 1993 Oct; 90(5):468-71. PubMed ID: 8219633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of thrombin in proliferative vitreoretinopathy.
    Bastiaans J; van Meurs JC; Mulder VC; Nagtzaam NM; Smits-te Nijenhuis M; Dufour-van den Goorbergh DC; van Hagen PM; Hooijkaas H; Dik WA
    Invest Ophthalmol Vis Sci; 2014 Jul; 55(7):4659-66. PubMed ID: 25015355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aclacinomycin A in the treatment of experimental proliferative vitreoretinopathy. Efficacy and toxicity in the rabbit eye.
    Steinhorst UH; Chen EP; Hatchell DL; Samsa GP; Saloupis PT; Westendorf J; Machemer R
    Invest Ophthalmol Vis Sci; 1993 Apr; 34(5):1753-60. PubMed ID: 8473115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of daunorubicin encapsulated in liposome for the treatment of proliferative vitreoretinopathy.
    Shinohara K; Tanaka M; Sakuma T; Kobayashi Y
    Ophthalmic Surg Lasers Imaging; 2003; 34(4):299-305. PubMed ID: 12875458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical management of proliferative vitreoretinopathy: an update.
    Khan MA; Brady CJ; Kaiser RS
    Retina; 2015 Feb; 35(2):165-75. PubMed ID: 25602631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of the molecular biologic milieu of the vitreous in proliferative vitreoretinopathy.
    Wladis EJ; Falk NS; Iglesias BV; Beer PM; Gosselin EJ
    Retina; 2013 Apr; 33(4):807-11. PubMed ID: 23222459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy.
    Charteris DG; Aylward GW; Wong D; Groenewald C; Asaria RH; Bunce C;
    Ophthalmology; 2004 Dec; 111(12):2240-5. PubMed ID: 15582080
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Vitrectomy with daunorubicin].
    Raczyńska K; Gebka A; Iwaszkiewicz-Bilikiewicz B; Ciechanowski C
    Klin Oczna; 2004; 106(3 Suppl):481-4. PubMed ID: 15636243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of retinal pigment epithelial cell-induced tractional retinal detachment by disintegrins, a group of Arg-Gly-Asp-containing peptides from viper venom.
    Yang CH; Huang TF; Liu KR; Chen MS; Hung PT
    Invest Ophthalmol Vis Sci; 1996 Apr; 37(5):843-54. PubMed ID: 8603869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ultrastructural studies of the blood-retina barrier after exposure to interleukin-1 beta or tumor necrosis factor-alpha.
    Claudio L; Martiney JA; Brosnan CF
    Lab Invest; 1994 Jun; 70(6):850-61. PubMed ID: 8015289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Vitreous substitutes as drug release systems].
    Szurman P; Frank C; Kaczmarek RT; Spitzer MS
    Klin Monbl Augenheilkd; 2009 Sep; 226(9):718-24. PubMed ID: 19750422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.